BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (January 2016)
26 slides from BioSpecifics Technologies's investor presentation, Jan 19, 2016
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE on ‘ten. Cr BioSpecifics January 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: Company Overview
Company Overview 0 © Originator i Profitable } Receives ! Future i BioSpecifics of collagenase =: biopharma ; revenues ! revenue growth : developing based-therapies | companywith { from XlAFLEX® {opportunities { XIAFLEX for ! lean corporate | milestones, : from robust ; medically structure and : foy
Slide 4: Unlocking Vast Potential of XIAFLEX
Unlocking Vast Potential of XIAFLEX® XIAFLEX: First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications Drive R&D in new indications to early proof-of-con
Slide 5: Marketed XIAFLEX Indications
Marketed XIAFLEX Indications: First, Effective Nonsurgical Treatment Options YTD Demand Growth of 44% Through 11/30/15
Slide 6: Dupuytren's Contracture
XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Collagen cord in hand causing one or more fingers to contract toward the palm Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Pre-treatment: Post-treatment: Source: Endo International ple
Slide 7: Commercial Highlights for Dupuytren's Contracture
Commercial Highlights for Dupuytren’s Contracture ~6,400 vials shipped 3Q15 in U.S. 14% year-over-year increase ~1.2 vials/patient First commercial sale in Japan in Sept. 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 E.U. label expansion approved in November
Slide 8: Peyronie's Disease
XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self
Slide 9: Commercial Highlights for Peyronie's Disease
Commercial Highlights for Peyronie’s Disease ~7,500 vials shipped 3Q15 in U.S. 33% year-over-year growth ~4,5 vials/patient Continued commercial progress and growth with certified physicians and new patients As of 3Q15 there were 2,325 certified physicians and 11,600 cumulative patients treated Appr
Slide 10: Pipeline Indications
XIAFLEX® Pipeline Indications
Slide 11: Pipeline Programs
XIAFLEX® Pipeline Programs Future Revenue-Generating Opportunities Preclinical ase 1 Phase 2 Phase 3 Phase 2b to initiate in Cellulite 10 1016 following Dec. 15 FDA meeting i Phase 2b to initiate Adhesive ¢ <0 > following 1016 FDA P meeting Human Phase 2 top-line Lipoma results 1H16 z Endo has licen
Slide 12: Adhesive Capsulitis
XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia » Long-term intensive physical the
Slide 13: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis
Phase 2b Study Results of XIAFLEX® in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results 321 patient double-blind, placebo-controlled study oe evaluating safety and efficacy in Stage 2 (frozen stage) 450 unilateral idiopathic frozen shoulder $40 | Primary endpoint: change in degrees from
Slide 14: Cellulite
XIAFLEX® for Cellulite Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects 85-98% of women (est.) and rarely affects men Phase 2a Study Design Randomized, double-blind multiple-dose Phase 2a study 150 women received up to three tre
Slide 15: Cellulite
XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study: Mid and high level XIAFLEX® doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” w
Slide 16: Human Lipomas
XIAFLEX® for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges under the skin Potential to be Only Approved No FDA-approved pharmaceutical therapies available Nonsurgical Surgery not practical for patients with multiple lipoma
Slide 17: Positive Phase Clinical Trial Results
Positive Phase 2 Clinical Trial Results Open label, dose escalation Phase 2 trial Statistically significant (p<0.0001) reduction in primary endpoint of surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of commercial dose) achieved best efficacy
Slide 18: Lipomas in Canines
XIAFLEX® for Lipomas in Canines Potential to be Only Approved Nonsurgical Therapy Key Complications Market Opportunity Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected
Slide 19: Uterine Fibroids
XIAFLEX® for Uterine Fibroids Clinical Trial to Begin in 2H16 Following Positive FDA. Meeting in Late 2015 Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key sei Cause pain, decreased fertility, pregnancy complications, miscarriage, Complications p y, pre
Slide 20: Lateral Hip Fat
XIAFLEX® for Lateral Hip Fat Early Opt-In by Partner Endo Definition & Complications Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their calo
Slide 21: Plantar Fibromatosis
XIAFLEX® for Plantar Fibromatosis Early Opt-In by Partner Endo Definition & Complications Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive
Slide 22: Endo Partnership for Development and Commercialization of XIAFLEX
Endo Partnership for Development and Commercialization of XIAFLEX® >$67.9M Received $67.9M received in licensing, sublicensing, milestone, to Date COGS, and royalty payments as of September 30, 2015 Low double digit royalties as % of net sales Additional mark-up on COGS Modest milestones for additio
Slide 23: Strong IP Portfolio
Strong IP Portfolio Long-term patent protection for XIAFLEX® Dupuytren’s Contracture Drug product composition patent until 2028 Biologic Exclusivity until 2022 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owne
Slide 24: Consistently Profitable Annually
Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/15 09/30/14 Cash and equivalents, and investments $32,824,471 $21,961,252 Income Statement Revenues $16,611,268 $9,396,976 Other income 65,056 53,189 Costs and expenses (6,062,469) (5,296,263) Provision
Slide 25: Anticipated Upcoming Pipeline Milestones
Anticipated Upcoming Pipeline Milestones UO Phase 2 placebo-controlled opt-in trial top-line i * Human Upomas results in 1H16 1 Initiate clinical trial in 2H16 following FDA meeting in Uterine Fibroids* late 2015 Adhesive Capsulitis U1 Initiate Phase 2b trial following 1016 FDA meeting OU Initiate P
Slide 26: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of: INJECTABLE COLLAGENASE ia BioSpecifics January 2016
Biospecifics Technologies — Investor Presentation (January 2016) on 6ix